Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089274 | 1.00 | CYP19A1 (0.45) | CYP19A1TBXA2RSCN5ASLC6A3KCNH2 | |
| SCHEMBL7808300 | 0.98 | CYP19A1 (0.46) | CYP19A1TBXA2RSCN5ASLC6A3KCNH2 | |
| SCHEMBL5864161 | 0.92 | CYP19A1 (0.47) | CYP19A1TBXA2RSCN5ASLC6A3LMNA | |
| SCHEMBL3688208 | 0.83 | CYP19A1 (0.44) | CYP19A1SCN5ALMNAHTTNPSR1 | |
| SCHEMBL7199600 | 0.81 | SIGMAR1 (0.57) | CYP19A1SIGMAR1 | |
| SCHEMBL5092009 | 0.80 | HRH1 (0.55) | CYP19A1TBXA2RSCN5ASLC6A3KCNH2 | |
| SCHEMBL14288444 | 0.80 | TBXA2R (0.46) | CYP19A1TBXA2RSCN5ASLC6A3KCNH2 | |
| SCHEMBL8251123 | 0.80 | HRH1 (0.55) | CYP19A1TBXA2RSCN5ASLC6A3KCNH2 | |
| SCHEMBL8120558 | 0.79 | SIGMAR1 (0.59) | CYP19A1KCNH2SIGMAR1 | |
| Fluorobenzene SCHEMBL7807000 | 0.78 | SLC18A3 (0.46) | SLC6A3SIGMAR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266784-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | CYP19A1 4615/4885TBXA2R 520/4885SCN5A 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.